Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).

Kei Muro,Takaki Yoshikawa,Kohei Shitara,Do-Youn Oh,Yoon-Koo Kang,Hyun Cheol Chung,Toshihiro Kudo,Keisho Chin,Shigenori Kadowaki,Yasuo Hamamoto,Shuichi Hironaka,Kazuhiro Yoshida,Chia-Jui Yen,Yasushi Omuro,Li Yuan Bai,Kaijiro Maeda,Akichika Ozeki,Reigetsu Yoshikawa,Yuko Kitagawa

Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC).

2018

Kei Muro
Takaki Yoshikawa
Kohei Shitara
Do-Youn Oh
Yoon-Koo Kang
Hyun Cheol Chung
Toshihiro Kudo
Keisho Chin
Shigenori Kadowaki
Yasuo Hamamoto
Shuichi Hironaka
Kazuhiro Yoshida
Chia-Jui Yen
Yasushi Omuro
Li Yuan Bai
Kaijiro Maeda
Akichika Ozeki
Reigetsu Yoshikawa
Yuko Kitagawa

4036Background: RAM (a human IgG1 antibody against vascular endothelial growth factor receptor-2) plus paclitaxel has been found to improve overall survival compared with paclitaxel alone as second...

Keywords:

Ramucirumab
Gastroesophageal Junction Adenocarcinoma
Pathology
Second-line therapy
Phases of clinical research
Oxaliplatin
Oncology
Paclitaxel
Internal medicine
Medicine
in patient
Vascular endothelial growth factor
first line therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations